Conference Coverage
Videos
NewsNetwork
OncLive® TV
Peer Exchange
Insights
Attend An Event
State of the Science Summit
Regional Seminar Series
OncLive Global Expo
Giants of Cancer Care
OncLive Community
SPECIALTY TOPICS
CURRENTLY VIEWING
All Specialties
Breast Cancer
Multiple Myeloma
Lung Cancer
Immuno-Oncology News
Gynecologic Oncology
Gastrointestinal Cancer
Colorectal Cancer
Ovarian Cancer
Prostate Cancer
Precision Medicine in Oncology®
Neoadjuvant HER2+
More >>
Related Articles
FDA Approval Sought for Subcutaneous Daratumumab in Multiple Myeloma
Rethinking Treatment Schemas in Relapsed/Refractory Multiple Myeloma
FDA Reviewing Isatuximab for Multiple Myeloma
Related Videos
Dr. Raje Highlights Treatment Options for Relapsed Multiple Myeloma
Emerging Therapies for Relapsed/Refractory Multiple Myeloma
Newly Diagnosed Myeloma: Transplant Ineligibility and Treatment
News >

Gene Expression Studies Offer Insight Into Myeloma Regimen's Efficacy

Published: Monday, Dec 19, 2016

Alessandra Di Bacco, PhD

Alessandra Di Bacco, PhD

An analysis of c-MYC expression in relapsed myeloma identified subgroups of patients with improved response to the combination of an immunomodulator and a proteasome inhibitor, according to data from a randomized trial presented during the 2016 ASH Annual Meeting.1
... to read the full story
To Read the Full Story
REGISTER
LOG IN

View Conference Coverage
Online CME Activities
TitleExpiration DateCME Credits
Community Practice Connections™: Advancing the Treatment of Bladder Cancers Using Evidence-Based Immuno-Oncology StrategiesJul 30, 20191.0
Medical Crossfire®: Where Are We Headed in the Treatment of Triple-Negative Breast Cancer?Jul 31, 20191.5
Publication Bottom Border
Border Publication
 
x